Click it and Unblock the Notifications
Just In
Don't Miss
-
Heeramandi Screening: Vicky Kaushal, Pulkit Samrat, Sooraj Pancholi- Bollywood Hunks In Traditional Style At R -
Pakistan vs New Zealand 4th T20 Live Score, Latest Updates From Lahore: Tom Blundell, Tim Robinson Open NZ Innings -
Tech Mahindra Q4 Results: Cons PAT Declines 41% YoY To Rs 661 Crore; Exits FY24 In Red -
Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here -
Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos -
AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley -
Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style! -
Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Ranbaxy, GlaxoSmithKline settle matters over Sumatriptan Succinate
New Delhi, Jan 21 (UNI) Ranbaxy Laboratories Ltd today announced that it has settled all matters relating to possible patent litigation with GlaxoSmithKline over Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex Tablets.
The terms of the settlement, provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg,50 mg and 100 mg strengths) in the United States with an expected launch date in December, 2008.
Additional terms of the settlement agreement were not disclosed.
The annual market sales for Sumatriptan Succinate (Imitrex) is 985 million dollars.
Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of generic medicines.
UNI
BJR
PBB
RN1445
